Shanghai Aislon Pharmaceutical Technology

Shanghai Aislon Pharmaceutical Technology (Aislon Pharma) is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of first-in-class and best-in-class small molecule drugs. The company primarily focuses on the DNA damage response (DDR) and protein degradation pathways to address unmet medical needs in oncology. Its lead candidate, ASL-001, is a highly selective inhibitor of Ubiquitin-specific protease 1 (USP1) designed to treat BRCA-deficient and other DDR-deficient cancers. Founded by industry veterans with extensive experience in global pharmaceutical R&D, Aislon Pharma utilizes a robust internal platform to advance a pipeline of precision medicines. The company is currently evaluating its lead program in Phase 1 clinical trials for advanced solid tumors. Aislon Pharma is backed by prominent venture capital firms including Qiming Venture Partners and TF Capital.